WO2019089672A1 - Composés spirocycliques à utiliser en tant que modulateurs du récepteur farnésoïde x - Google Patents

Composés spirocycliques à utiliser en tant que modulateurs du récepteur farnésoïde x Download PDF

Info

Publication number
WO2019089672A1
WO2019089672A1 PCT/US2018/058326 US2018058326W WO2019089672A1 WO 2019089672 A1 WO2019089672 A1 WO 2019089672A1 US 2018058326 W US2018058326 W US 2018058326W WO 2019089672 A1 WO2019089672 A1 WO 2019089672A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclopropyl
alkyl
azaspiro
independently
mmol
Prior art date
Application number
PCT/US2018/058326
Other languages
English (en)
Inventor
Joseph E. CARPENTER
Yanting Huang
Ying Wang
Gang Wu
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP18804190.9A priority Critical patent/EP3704114B1/fr
Priority to AU2018357878A priority patent/AU2018357878A1/en
Priority to JP2020544335A priority patent/JP7228595B2/ja
Priority to BR112020008157-4A priority patent/BR112020008157A2/pt
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority to CA3081424A priority patent/CA3081424A1/fr
Priority to MX2020004400A priority patent/MX2020004400A/es
Priority to CN201880069863.0A priority patent/CN111278821B/zh
Priority to SG11202003825TA priority patent/SG11202003825TA/en
Priority to EA202091101A priority patent/EA202091101A1/ru
Priority to ES18804190T priority patent/ES2933184T3/es
Priority to KR1020207015273A priority patent/KR20200083528A/ko
Priority to PE2020000676A priority patent/PE20201184A1/es
Publication of WO2019089672A1 publication Critical patent/WO2019089672A1/fr
Priority to IL274322A priority patent/IL274322A/en
Priority to CONC2020/0005486A priority patent/CO2020005486A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Definitions

  • the present invention relates generally to compounds useful as farnesoid X receptor (FXR) modulators, pharmaceutical compositions comprising such compounds and to their use in therapy, especially in the treatment or prophylaxis of diseases, disorders, and conditions for which an FXR modulator is indicated.
  • FXR farnesoid X receptor
  • FXR or NR1H4 is a nuclear receptor that can activate the expression of specific target genes in a ligand-dependent manner.
  • FXR is expressed in the liver, throughout the gastrointestinal tract, colon, ovary, adrenal gland, kidney, and in the gall bladder and biliary tree in humans.
  • FXR forms a heterodimer with Retinoid X Receptor (RXR) and binds to specific response elements in target genes to regulate gene transcription (B. M. Forman et al, Cell 1995; 81 : 687; W. Seol et al, Mol. Endocrinol. 1995; 9: 72).
  • the FXR/RXR heterodimer typically binds to an inverted repeat of a consensus hexanucleotide sequence (AGGTCA) separated by a single nucleotide, i.e. an IR-1 sequence.
  • AGGTCA consensus hexanucleotide sequence
  • the relevant physiological ligands of FXR are bile acids including chenodeoxycholic acid and its taurine-conjugate (D. J. Parks et al., Science 1999; 284: 1365; M. Makishima et al., Science 1999; 284: 1362).
  • FXR activation regulates the expression of multiple genes that encode enzymes and transporters involved in bile acid synthesis, influx, and efflux from the liver and intestine resulting in a net decrease in total endogenous bile acids in a negative feedback loop.
  • FXR is involved in paracrine and endocrine signaling by upregulating the expression of the cytokine Fibroblast Growth Factor 15 (rodents) or 19 (primates), which can also contribute to the regulation of bile acid concentrations (Holt et al., Genes Dev. 2003; 17: 1581 ; Inagaki et al, Cell Metab 2005; 2: 217). Therefore, FXR is considered to be a master regulator of bile acid homeostasis.
  • FXR agonists are for the treatment of diseases in which bile acids are dysregulated, including cholestatic diseases (e.g. primary biliary cirrhosis and primary sclerosing cholangitis) that can lead to fibrosis, cirrhosis, cholangiocarcinoma,
  • cholestatic diseases e.g. primary biliary cirrhosis and primary sclerosing cholangitis
  • fibrosis cirrhosis
  • cholangiocarcinoma cholangiocarcinoma
  • bile acids also affect the microflora and integrity of the small intestine. Obstruction of bile flow in humans or rodents causes proliferation of intestinal bacteria and mucosal injury, which can lead to bacterial translocation across the mucosal barrier and systemic infection (Berg, Trends Microbiol. 1995; 3: 149-154).
  • mice lacking FXR have increased ileal levels of bacteria and a compromised epithelial barrier, while activation of intestinal FXR plays an important role in preventing bacterial overgrowth and maintaining the integrity of the intestinal epithelium (Inagaki et al, Proc Natl Acad Sci 2006; 103: 3920-3925). Over time, FXR null mice spontaneously develop hepatocellular carcinoma, and this can be abrogated by selective re-activation of FXR in the intestine (Degirolamo et al., Hepatology 61 : 161-170).
  • Pharmacological activation of FXR with a small molecule agonist or transgenic expression of FXR in the intestine can normalize bile acid concentrations, decrease cellular proliferation in hepatic bile ducts, and reduce inflammatory cell infiltration, necrotic area, and liver fibrosis in rodent models of cholestasis (Liu et al., J. Clin. Invest. 2003; 112: 1678-1687; Modica et al,
  • FXR agonists regulate the hepatic expression of hundreds of genes encoding proteins involved in cholesterol and lipid metabolism and transport, glucose homeostasis, inflammation, chemotaxis, and apoptosis among other pathways (Zhan et al, PLoS One 2014; 9: el05930; Ijssennagger et al, J Hepatol 2016; 64: 1158-1166).
  • FXR agonists have also been investigated in preclinical models of fibrosis, cancer, inflammatory diseases, and metabolic disorders, including dyslipidemia, obesity, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome (Crawley, Expert Opin. Ther. Patents 2010; 20: 1047-1057).
  • NAFLD nonalcoholic steatohepatitis
  • T2DM type 2 diabetes mellitus
  • T2DM insulin resistance
  • hypertension hypertension
  • dyslipidemia dyslipidemia
  • NASH is the most severe and progressive form of NAFLD and includes the histological findings of hepatic steatosis, inflammation, and ballooning degeneration with varying amounts of pericellular fibrosis (Sanyal et al, Hepatology 2015; 61 : 1392-1405).
  • the present invention provides novel compounds for treating a disease, disorder, or condition associated with farnesoid X receptor (FXR) activity in a patient in need thereof.
  • FXR farnesoid X receptor
  • the present invention provides compounds of Formula (I), Formula (II) and Formula (III) as well as the subgenera and species thereof, including stereoisomers, tautomers, pharmaceutically acceptable salts, and solvates thereof, which are useful as FXR modulators.
  • the present invention also provides processes and intermediates for making the compounds of the present invention.
  • the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof.
  • the compounds of the invention may be used in therapy, either alone or in combination with one or more additional therapeutic agents.
  • the compounds of the invention may be used in the treatment of a disease, disorder, or condition associated with activity of farnesoid X receptor (FXR) in a patient in need of such treatment by administering a therapeutically effective amount of the compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, to the patient.
  • FXR farnesoid X receptor
  • the disease, disorder, or condition may be related to pathological fibrosis.
  • the compounds of the invention can be used alone, in combination with one or more compounds of the present invention, or in combination with one or more, e.g., one to two, other therapeutic agents.
  • the compounds of the invention may be used, either as a single agent or in combination with other agents, in the treatment of a disease, disorder, or condition selected from nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), and primary biliary cirrhosis (PBC).
  • NASH nonalcoholic steatohepatitis
  • NAFLD non-alcoholic fatty liver disease
  • PSC primary sclerosing cholangitis
  • PBC primary biliary cirrhosis
  • IPF idiopathic pulmonary fibrosis
  • the compounds of the invention may be used for the manufacture of a medicament for the treatment of a disease, disorder, or condition in a patient in need of such treatment.
  • the present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable salt and solvate forms thereof, according to Formula (I).
  • the present application also provides pharmaceutical compositions containing at least one compound according to Formula (I), or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or a solvate thereof, and optionally at least one additional therapeutic agent.
  • the present application provides methods for treating a patient suffering from a FXR-modulated disease or disorder such as for example, biliary fibrosis, liver fibrosis, renal fibrosis, Non-Alcoholic Fatty Liver Disease (NAFLD), Non- Alcoholic Steato-Hepatitis (NASH), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and pancreatic fibrosis, by administering to a patient in need of such treatment a therapeutically effective amount of a compound of the present invention, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or a solvate thereof, and optionally in combination with at least one additional therapeutic agent.
  • a FXR-modulated disease or disorder such as for example, biliary fibrosis, liver fibrosis, renal fibrosis, Non-Alcoholic Fatty Liver Disease (NAFLD), Non- Alcoholic Steato-Hepati
  • the present invention provides a compound of Formula (I):
  • X 1 and X 4 are each independently C or N;
  • X 2 and X 3 are each independently CR 5 , N, NR 6 , O, or S;
  • E ring is a 4- to 6-membered carbocyclyl or heterocyclyl, wherein the carbocyclyl and heterocyclyl are each independently substituted with 0 to 3 R 3 ;
  • Y is CR 7 or N
  • n are each independently an integer of 0, 1, or 2;
  • f is an integer of 0, 1 , 2, or 3;
  • Z is 6- to 10-membered aryl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, and S, 3- to 10-membered carbocyclyl, or 4- to 10- membered heterocyclyl containing 1 to 3 heteroatoms independently selected from N, O, and S, wherein the aryl, heteroaryl carbocyclyl, and heterocyclyl are independently substituted with 0 to 5 R 8 ;
  • L 1 is a covalent bond, O, S, NR 16 , -S(0) 2 -, Ci-3 alkylene, Ci-3 heteroalkylene, C2-4 alkenylene, C2-4 alkynylene, aryl, or a 5- to 6-membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, and S containing 1 to 4 heteroatoms independently selected from N, O, and S; wherein the alkylene, alkenylene, aryl, heteroalkylene, and heteroaryl are each independently substituted with 0 to 3 R 11 ;
  • L 2 is a covalent bond, O, S, NR 17 , C1-3 alkylene, or C1-3 heteroalkylene, wherein the alkylene and heteroalkylene are independently substituted with 0 to 3 R 15 ;
  • R x is -L -R z ;
  • L 3 is a covalent bond, a C1-3 alkylene, -C(0)NR 12 -CH2- or -OCH2-, wherein the C1-3 alkylene is substituted with 0 to 3 R 4 ;
  • R z is -CN, -C(0)OR 13 , -C(0)NR 14a R 14b ,
  • R e is Ci-6 alkyl, C3-6 cycloalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, or haloalkoxyalkyl;
  • each R Y is independently hydrogen, halo, cyano, hydroxyl, amino, Ci-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; or alternatively two R Y , together with the carbon atoms to which they are attached, form a bridge moiety; and with the proviso that when Y is N and R Y is attached to a carbon atom adjacent to Y, then R Y is not halo, cyano, hydroxyl, amino, alkoxy, or haloalkoxy;
  • R 1 is Ci-6 alkyl, C3-5 cycloalkyl, or C4-6 heterocyclyl, wherein the alkyl or cycloalkyl is substituted with 0 to 3 R 9 ;
  • R 2 is 6- to 10-membered aryl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, and S, 3- to 10-membered carbocyclyl, or 4- to 10- membered heterocyclyl containing 1 to 3 heteroatoms independently selected from N, O, and S, wherein the aryl, heteroaryl, carbocyclyl, and heterocyclyl are independently substituted with 0 to 5 R 10 ;
  • R 3 , R 5 and R 7 are each independently hydrogen, halo, cyano, hydroxyl, amino, Ci-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
  • R 4 is each independently halo, oxo, cyano, hydroxyl, amino, alkyl, alkoxy, or alkylamino; or alternatively, two R 4 , taken together with the atom(s) to which they are attached, form a carbocyclyl or heterocyclyl moiety;
  • R 6 , R 16 and R 17 are each independently hydrogen, Ci-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, or haloalkoxyalkyl;
  • R a is each independently Ci-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl,
  • R b is each independently hydrogen or R a ;
  • R c is each independently R b or alternatively, the two R c are taken together with the nitrogen atom to which they are bonded form a 4-, 5-, 6- or 7-membered heterocyclyl containing 1 to 3 heteroatoms independently selected from N, O, and S;
  • R d is each independently selected from R a , alkoxy, haloalkoxy, alkylamino,
  • cycloalkylamino, heterocyclylamino, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkoxy, heterocyclyloxy, haloalkoxy, alkoxyalkoxy, haloalkylamino, alkoxyalkylamino, haloalkoxyalkylamino, arylamino, aralkylamino, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, alkylthio, halo, cyano, hydroxyl, amino, oxo, -OR a , -SR a , S,
  • R 9 is each independently halo, cyano, hydroxyl, amino, or Ci-6 alkyl
  • R 11 and R 15 are each independently halo, oxo, cyano, hydroxyl, amino, Ci-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
  • R 12 is hydrogen or Ci-4 alkyl
  • R 13 is hydrogen, Ci-10 alkyl, glycosyl, or carboxy(trihydroxy)tetrahydropyranyl
  • R 14a and R 14b are each independently hydrogen, Ci-6 alkyl, C3-6 cycloalkyl, C4-6
  • heterocyclyl alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy.
  • dashed circle denotes an aromatic ring formed by X 1 , X 2 , X 3 , X 4 , and the carbon atom; and the dashed straight lines are each independently an optional covalent bond.
  • X 2 is N or NR 6 .
  • R Y together form a C1-3 alkylene bridge moiety.
  • R Y )f denotes one or more optional substituent groups on any of the suitable ring member atoms, and each of R Y is independent and can be the same or different.
  • L 1 is a covalent bond, O, S, NH, Ci-3 alkylene, -(C1-3 alky lene) a -0-(C 1-3 alkylene)b- -(C1-3 alkylene) a -S-(Ci- 3 alkylene)b-, or -(C1-3 alky lene) a -NH-(C 1-3 alkylene)b-, wherein the C1-3 alkylene is substituted with 0 to 3 R 11 ; a is an integer of 0 or 1 ; b is an integer of 0 or 1 ; provided that a and b are not both 1 ; and L 2 is a covalent bond.
  • the E ring is a moiety selected from:
  • E 1 and E 2 are independently CR 3 , CHR 3 , N, NR 3 , O or S;
  • the dashed line is an optional covalent bond; that is, the dashed line denotes a covalent bond which is either present or absent;
  • t 0, 1 or 2;
  • each R 3 is independently hydrogen, halo, cyano, hydroxyl, amino, Ci-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy.
  • Z is phenyl or 5- to 10- membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, and S containing 1 to 3 heteroatoms independently selected from N, O, and S, wherein the phenyl and heteroaryl are independently substituted with 0 to 5 R 8 , wherein R 8 is the same as defined above.
  • L 1 is a covalent bond.
  • -Z-R x is
  • Y is N.
  • Y is CH; and L 1 is a covalent bond, O, S, NH, -0-(Ci_ 3 alkylene)-, -S-(Ci_ 3 alkylene)-, or -NH-(Ci_ 3 alkylene)-.
  • R 2 is phenyl or 6- membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, and S containing 1 to 3 heteroatoms independently selected from N, O, and S, wherein the phenyl or heteroaryl is substituted with 0 to 3 R 10 .
  • L 2 is a covalent bond.
  • X 1 is C or N
  • X 2 and X 3 are each independently CH, N, O, or S;
  • Z is phenyl or a 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, and S containing 1 to 3 heteroatoms independently selected from N, O, and S, wherein the phenyl and heteroaryl are independently substituted with 0 to 3 R 8 ;
  • R x is -C(0)OR 13 or -C(0)NH-S(0) 2 R e ;
  • R e is Ci-6 alkyl or C3-6 cycloalkyl;
  • R 1 is Ci-6 alkyl or C3-5 cycloalkyl, wherein the alkyl or cycloalkyl is substituted with 0 to 3 R 9 ;
  • R 2 is phenyl or 6-membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, and S containing 1 to 3 heteroatoms independently selected from N, O, and S, wherein the phenyl or heteroaryl is substituted with 0 to 3 R 10 ;
  • R 8 , R 9 , R 10 , and R 13 are the same as defined above.
  • R 2 is phenyl or pyridinyl, each of which is independently substituted with 0 to 3 R 10 .
  • Z is 8- to 10-membered bicyclic heteroaryl, wherein the heteroaryl is independently substituted with 0 to 3 R 8 .
  • R x is -C(0)OH.
  • the present compounds are represented by Formula (III):
  • Z is 6-membered monocyclic heteroaryl containing 1 or 2 nitrogen atoms, or a 9- to 10 membered bicyclic heteroaryl containing 1 or 3 heteroatoms independently selected from N, O, and S, wherein the monocyclic or bicyclic heteroaryl is independently substituted with 0 to 3 R 8 ;
  • R 2 is phenyl or pyridinyl, wherein the phenyl and pyridinyl are each independently
  • R 8 is each independently halo, cyano, hydroxyl, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 alkoxy, or
  • R 10 is each independently halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 alkoxy, or Ci-4 haloalkoxy;
  • R x is -C(0)OH or -C(0)NH-S(0) 2 R e ;
  • R e is Ci-6 alkyl or C3-6 cycloalkyl.
  • Z is a heteroaryl selected from pyridinyl, benzthiazolyl, pyrrolopyridinyl, pyrrolopyrimidinyl, indolyl, quinolinyl, imidazopyridinyl, pyrazolopyrimidinyl, and pyrrolotriazinyl, wherein the heteroaryl is independently substituted with 0 to 3 R 8 . In some embodiments, the heteroaryl is independently substituted with 0, 1, or 2 R 8 .
  • R 2 is phenyl or pyridinyl, wherein the phenyl and pyridinyl are each independently substituted with 1 or 2 R 10 .
  • R 8 is each independently F, -CH3, -OCH3, -OCH2CH3, -OCH(CH 3 ) 2 , -CF3, -OCF3, or -OCHF2.
  • R 10 is each independently CI, -CH3, -CF3,
  • R x is -C(0)OH or -C(0)NH-S(0) 2 R e ; and R e is methyl, ethyl, isopropyl, or cyclopropyl.
  • X 1 is C.
  • X 2 is N.
  • X 3 is O.
  • Formula X 4 is C.
  • X 1 is C and X 4 is C.
  • one of X 2 and X 3 is N and the other of X 2 and X 3 is O.
  • X 2 is N and X 3 is O.
  • X 2 is O and X 3 is N.
  • X 1 is C; X 2 is N; and X 3 is O. In one embodiment of Formula (I), X 1 is C; one of X 2 and X 3 is N and the other of and X 3 is O; and X 4 is C.
  • X 1 is C; X 2 is N; X 3 is O; and X 4 is C.
  • X 1 is C; X 2 is O; X 3 is N; and X 4 is C.
  • L 1 is a covalent bond, O, -CH2-, -CH2CH2-, -OCH2-, -CH2OCH2-, or -NR 16 -. Included in this embodiment are compounds in which L 1 is a covalent bond, O, or -OCH2-. Also included in this embodiment are compounds in which L 1 is a covalent bond.
  • the moiety is selected from:
  • L 1 is a covalent bond, O, -CH 2 - -CH2CH2-, -OCH2-, -CH2OCH2-, or -NR 16 -. Included in this embodiment are compounds in which L 1 is a covalent bond, O, or -OCH2-. Also included in this embodiment are compounds in which L 1 is a covalent bond.
  • L 1 is a covalent bond, -CH2-, -CH2CH2-, or -CH2OCH2-. Included in this embodiment are compounds in which L 1 is a covalent bond.
  • L 1 is a covalent bond, O, -CH2- -CH2CH2-, -OCH2-, -CH2OCH2-, or -NR 16 -. Included in this embodiment are compounds in which L 1 is a covalent bond, O, or -OCH2-. Also included in this embodiment are compounds in which L 1 is a covalent bond.
  • Z is aryl or 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, and S, wherein the phenyl and heteroaryl are independently substituted with 0 to 5 R 8 .
  • Z is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzo[d]imidazolyl, benzo[d]isoxazolyl, benzo[d]oxadiazolyl, benzo[d]thiazolyl, imidazolo[l,5-a]pyridinyl, indazolyl, indolyl, pyrazolo[4,3-b] pyridinyl, pyrrolo[2,l-f] [l,2,4]triazinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[2,3- d] pyrimidinyl, pyrrolo[3,2-c]pyridinyl, thiazolo[4,5-b]pyridinyl, thiazolo[5,4-b]pyri
  • L 1 is a covalent bond, O, or -OCH2-;
  • Z is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzo[d]imidazolyl,
  • L is a covalent bond, -CH2-, -CH2CH2-, -C(0)NHCH 2 - or -OCH2-.
  • L is a covalent bond.
  • L 3 is -CH2-, -CH2CH2-, -C(0)NHCH 2 - or -OCH2-.
  • L 3 is a covalent bond or -C(0)NHCH 2 -
  • R z is -CN, -C( 13 , -C(0)NR 14a R 14b ,
  • R x is -CN, -C(0)OH, -C(0)0(Ci-3 alkyl), -C(0)NH 2 , -C(0)NH(Ci- 3 alkyl), -C(0)NH(C 3 - 6 cyclopropyl), -C(0)NHCH 2 C(0)OH, -C(0)NHS(0) 2 (Ci- 3 alkyl), -C(0)NHS(0) 2 (C 3 -6 cyclopropyl), -OCH2C(0)OH, or -C(0)0(carboxy(trihydroxy)tetrahydropyranyl).
  • R x is -CN, -C(0)OH
  • L 2 is a covalent bond or -CH(cyclopropyl)-.
  • L 2 is a covalent bond.
  • L 2 is
  • R 2 is cyclopropyl
  • R 2 is C3-6 cycloalkyl, phenyl, or pyridinyl, wherein the phenyl and the pyridinyl are independently substituted with 1 to 3 R 10 .
  • R 2 is cyclopropyl, cyclohexyl, phenyl, or pyridinyl, wherein the phenyl and the pyridinyl are independently substituted with 1 to 3 R 10 .
  • R 2 is cyclohexyl, phenyl, or pyridinyl, wherein the phenyl and the pyridinyl are independently substituted with 1 to 3 R 10 ; and L 2 is a covalent bond.
  • R 1 is C1-3 alkyl, C3-4 cycloalkyl, or C4-5 heterocyclyl, wherein the alkyl, cycloalkyl, and heterocyclyl are each substituted with 0 to 3 R 9 ;
  • R 1 is -CHF2, -CH(CH3)2, cyclopropyl, or methylcyclopropyl.
  • One embodiment provides a compound according to Formula (I) wherein:
  • X 1 is C, X 2 is N, X 3 is O, and X 4 is C; or X 1 is N, X 2 is N, X 3 is C, and X 4 is C;
  • L 1 is a covalent bond, O, or -OCH2-, provided that L 1 is a covalent bond when Y is N;
  • Z is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzo[d]imidazolyl,
  • R 8 is F, -CH 3 , -CF 3 , -OCH3, -OCH2CH3, -OCH(CH 3 ) 2 , -OCHF2, -OCF3, -OCH2CH2OH, or -CH20CH2CH 2 Si(CH 3 )3;
  • R x is -CN, -C(0)OH, -C(0)OCH 2 CH 3 , -C(0)NH 2 , -C(0)NH(CH 3 ), -C(0)NHCH 2 CH 3 , -C(0)NHCH(CH 3 ) 2 , -C(0)NH(cyclopropyl), -C(0)NHCH 2 C(0)OH,
  • L 2 is a covalent bond
  • R 1 is -CHF2, -CH(CH 3 )2, cyclopropyl, or methylcyclopropyl;
  • R 2 is cyclohexyl, phenyl, or pyridinyl, wherein the phenyl and the pyridinyl are
  • R 10 is each independently F, CI, -CH 3 , -CF 3 , -OCH 3 , or -OCF 3 .
  • the present compounds are represented by Formula (III) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof; wherein: Z is a 9- to 10-membered bicyclic heteroaryl containing 1 or 3 heteroatoms independently selected froni N, O, and S, wherein the bicyclic heteroaryl is independently substituted with 0 to 3 R 8 ;
  • R 2 is phenyl or pyridinyl, wherein the phenyl and pyridinyl are each independently
  • R 8 is each independently F, CI, cyano, hydroxyl, C1-3 alkyl, C1-2 haloalkyl, C1-3 alkoxy, or Ci-2 haloalkoxy;
  • R 10 is each independently F, CI, C1-3 alkyl, C1-2 fluoroalkyl, Ci-4 alkoxy, or C1-2
  • R x is -C(0)OH.
  • the present compounds are represented by Formula (III) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof; wherein: Z is a 9-membered bicyclic heteroaryl containing 1 or 3 heteroatoms independently selected from N, O, and S, wherein the bicyclic heteroaryl is independently substituted with 0 to 3 R 8 ;
  • R 2 is phenyl or pyridinyl, wherein the phenyl and pyridinyl are each independently
  • R 8 is each independently F, CI, cyano, hydroxyl, C1-3 alkyl, C1-2 haloalkyl, C1-3 alkoxy, or Ci-2 haloalkoxy;
  • R 10 is each independently F, CI, C1-3 alkyl, C1-2 fluoroalkyl, Ci-4 alkoxy, or C1-2
  • R x is -C(0)OH.
  • the present invention provides compounds selected from:
  • the present invention provides, inter alia, compounds selected from any one of the Examples as described in the specification, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof.
  • the compounds of the present invention have FXR EC50 values
  • the compounds of the present invention have FXR EC50 values ⁇ 1000 nM; in another embodiment, the compounds of the present invention have FXR EC50 values ⁇ 500 nM; in another embodiment, the compounds of the present invention have FXR EC50 values
  • the compounds of the present invention have FXR EC50 values ⁇ 100 nM; in another embodiment, the compounds of the present invention have FXR EC50 values ⁇ 50 nM.
  • the present invention provides a composition comprising at least one of the compounds of the present invention, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or a solvate thereof.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or a solvate thereof.
  • the present invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a
  • the present invention provides a process for making a compound of the present invention. In another embodiment, the present invention provides an intermediate for making a compound of the present invention.
  • the present invention provides a pharmaceutical composition as defined above further comprising one or more additional therapeutic agents.
  • the present invention provides a method for the treatment of a disease, disorder, or condition associated with dysregulation of bile acids in a patient in need of such treatment, and the method comprises administering a therapeutically effective amount of a compound of the present invention, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, to the patient.
  • the present invention provides a method for the treatment of a disease, disorder, or condition associated with activity of farnesoid X receptor (FXR) in a patient in need of such treatment comprising administering a therapeutically effective amount of a compound of the present invention, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, to the patient.
  • FXR farnesoid X receptor
  • the present invention provides a method for the treatment of the disease, disorder, or condition comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
  • the present invention provides a method for eliciting an farnesoid X receptor (FXR) agonizing effect in a patient comprising administering a therapeutically effective amount of a compound of the present invention, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, to the patient.
  • FXR farnesoid X receptor
  • the disease, disorder, or condition is associated with FXR dysfunction include pathological fibrosis, cancer, inflammatory disorders, metabolic, or cholestatic disorders.
  • the disease, disorder, or condition is associated with fibrosis, including liver, biliary, renal, cardiac, dermal, ocular, and pancreatic fibrosis.
  • the disease, disorder, or condition is associated with cell- proliferative disorders, such as cancer.
  • the cancer includes solid tumor growth or neoplasia.
  • the cancer includes tumor metastasis.
  • the cancer is of the liver, gall bladder, small intestine, large intestine, kidney, prostate, bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, genitalia, genitourinary tract, head, larynx, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, skin, spleen, stomach, testicle, or thyroid.
  • the cancer is a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma.
  • diseases, disorders, or conditions associated with the activity of FXR include, but are not limited to, transplant injection, fibrotic disorders (e. g., liver fibrosis, kidney fibrosis), inflammatory disorders (e.g., acute hepatitis, chronic hepatitis, non-alcoholic steatohepatitis (NASH), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD)), as well as cell-proliferative disorders (e.g., cancer, myeloma, fibroma,
  • hepatocellular carcinoma colorectal cancer, prostate cancer, leukemia, Kaposi's sarcoma, solid tumors.
  • fibrotic disorders, inflammatory disorders, as well as cell-proliferative disorders include, but are not limited to, non-alcoholic fatty liver disease (NAFLD), alcoholic or non-alcoholic steatohepatitis (NASH), acute hepatitis, chronic hepatitis, liver cirrhosis, primary biliary cirrhosis, primary sclerosing cholangitis, drug-induced hepatitis, biliary cirrhosis, portal hypertension, regenerative failure, liver hypofunction, hepatic blood flow disorder, nephropathy, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, benign prostatic hyperplasia, neuropathic bladder disease, diabetic nephropathy, focal segmental glomerulosclerosis, IgA nephropathy, nephropathy induced by drugs or transplantation, autoimmune nephropathy,
  • NAFLD non-alcoholic fatty liver disease
  • NASH non
  • the present invention provides a method for the treatment of a fibrotic disorder, an inflammatory disorder, or a cell-proliferative disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
  • the present invention provides a compound of the present invention for use in therapy.
  • the present invention provides a compound of the present invention for use in therapy for the treatment of a fibrotic disorder, an inflammatory disorder, or a cell-proliferative disorder thereof.
  • the present invention also provides the use of a compound of the present invention for the manufacture of a medicament for the treatment of a fibrotic disorder, an inflammatory disorder, or a cell-proliferative disorder thereof.
  • the present invention provides a method for the treatment of a fibrotic disorder, an inflammatory disorder, or a cell-proliferative disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a first and second therapeutic agent, wherein the first therapeutic agent is a compound of the present invention.
  • the present invention provides a combined preparation of a compound of the present invention and additional therapeutic agent(s) for simultaneous, separate or sequential use in therapy.
  • the present invention provides a combined preparation of a compound of the present invention and additional therapeutic agent(s) for simultaneous, separate or sequential use in the treatment of a fibrotic disorder, an inflammatory disorder, or a cell-proliferative disorder.
  • the compounds of the present invention may be employed in combination with additional therapeutic agent(s), such as one or more anti-fibrotic and/or anti-inflammatory therapeutic agents.
  • compositions or combined methods or combined uses are selected from one or more, preferably one to three, of the following therapeutic agents: TGF receptor inhibitors (for example, galunisertib), inhibitors of TGF synthesis (for example, pirfenidone), inhibitors of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) receptor kinases (for example, nintedanib), humanized anti-av 6 integrin monoclonal antibody (for example, 3G9), human recombinant pentraxin-2, recombinant human Serum Amyloid P, recombinant human antibody against TGF -l, -2, and -3, endothelin receptor antagonists (for example, macitentan), interferon gamma, c-Jun amino-terminal kinase (INK) inhibitor (for example, 4-[[9-[(3S)-tetrahydro-3-furanyl]-8
  • the therapeutic agents useful for the treatment of such fibrotic conditions include, but are not limited to, FXR agonists (for example OCA, GS-9674, and LJN452), LOXL2 inhibitors (for example pumpuzumab), LPA1 antagonists (for example, BMS-986020 and SAR 100842), PPAR modulators (for example, elafibrinor, pioglitazone, and saroglitazar, IVA337), SSAO/VAP-1 inhibitors (for example, PXS-4728A and SZE5302), ASK-1 inhibitors (for example GS-4997 or selonsertib), ACC inhibitors (for example, CP-640186 and NDI-010976 or GS-0976), FGF21 mimetics (for example, LY2405319 and BMS-986036), caspase inhibitors (for example, emricasan), NOX4 inhibitors (for example, GKT137831),
  • the FXR agonists of various embodiments of the present invention may also be used in combination with one or more therapeutic agents such as CCR2/5 inhibitors (for example, cenicriviroc), Galectin-3 inhibitors (for example, TD-139, GR-MD-02), leukotriene receptor antagonists (for example, tipelukast, montelukast), SGLT2 inhibitors (for example, dapagliflozin, remogliflozin), GLP-1 receptor agonists (for example, liraglutide and semaglutide), FAK inhibitors (for example, GSK-2256098), CBl inverse agonists (for example, JD-5037), CB2 agonists (for example, APD-371 and JBT-101), autotaxin inhibitors (for example,
  • CCR2/5 inhibitors for example, cenicriviroc
  • Galectin-3 inhibitors for example, TD-139, GR-MD-02
  • leukotriene receptor antagonists for
  • additional therapeutic agent(s) used in combined pharmaceutical compositions or combined methods or combined uses are selected from one or more, preferably one to three, of immunoncology agents, such as Alemtuzumab, Atezolizumab, Ipilimumab, Nivolumab, Ofatumumab, Pembrolizumab, and Rituximab.
  • immunoncology agents such as Alemtuzumab, Atezolizumab, Ipilimumab, Nivolumab, Ofatumumab, Pembrolizumab, and Rituximab.
  • the compounds of this invention can be administered for any of the uses described herein by any suitable means, for example, orally, such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard
  • composition means a composition comprising a compound of the invention in combination with at least one additional pharmaceutically acceptable carrier.
  • a “pharmaceutically acceptable carrier” refers to media generally accepted in the art for the delivery of biologically active agents to animals, in particular, mammals, including, i.e. , adjuvant, excipient or vehicle, such as diluents, preserving agents, fillers, flow regulating agents, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, anti-bacterial agents, anti-fungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.
  • Pharmaceutically acceptable carriers are formulated according to a number of factors well within the purview of those of ordinary skill in the art. These include, without limitation: the type and nature of the active agent being formulated; the subject to which the agent-containing composition is to be administered; the intended route of administration of the composition; and the therapeutic indication being targeted. Pharmaceutically acceptable carriers include both aqueous and nonaqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, e.g. , stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, are found in a variety of readily available sources such as, for example, Remington 's Pharmaceutical Sciences, 18th Edition ( 1990).
  • beneficial or desired clinical results include, but are not limited to, one or more of the following: decreasing the severity and/or frequency one or more symptoms resulting from the disease, disorder, or condition; diminishing the extent of or causing regression of the disease, disorder, or condition; stabilizing the disease, disorder, or condition (e.g. , preventing or delaying the worsening of the disease, disorder, or condition); delay or slowing the progression of the disease, disorder, or condition; ameliorating the disease, disorder, or condition state;
  • the dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired.
  • the daily oral dosage of each active ingredient when used for the indicated effects, will range between about 0.01 to about 5000 mg per day, preferably between about 0.01 to about 1000 mg per day, and most preferably between about 0.01 to about 250 mg per day. Intravenously, the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion.
  • Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily. The compounds are typically administered in admixture with suitable
  • pharmaceutical carriers suitably selected with respect to the intended form of
  • Dosage forms suitable for administration may contain from about 0.1 milligram to about 2000 milligrams of active ingredient per dosage unit.
  • the active ingredient will ordinarily be present in an amount of about 0.1-95% by weight based on the total weight of the composition.
  • a typical capsule for oral administration contains at least one of the compounds of the present invention (250 mg), lactose (75 mg), and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.
  • a typical injectable preparation is produced by aseptically placing at least one of the compounds of the present invention (250 mg) into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of the present invention, alone or in combination with a pharmaceutical carrier.
  • compounds of the present invention can be used alone, in combination with other compounds of the invention, or in combination with one or more, preferably one to three, other therapeutic agent(s), e.g. , ASK-1 inhibitors, CCR2/5 antagonists, autotaxin inhibitors, LPA1 receptor antagonists or other pharmaceutically active material.
  • one active ingredient may be enteric coated.
  • enteric coating one of the active ingredients it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines.
  • One of the active ingredients may also be coated with a material that affects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients.
  • the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine.
  • Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components.
  • HPMC hydroxypropyl methylcellulose
  • the polymer coating serves to form an additional barrier to interaction with the other component.
  • the compounds of the present invention can be administered alone or in
  • each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect.
  • the compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving FXR agonists.
  • Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving FXR agonist activity.
  • a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound.
  • compounds according to the present invention could be used to test their effectiveness.
  • the present invention also encompasses an article of manufacture.
  • article of manufacture is intended to include, but not be limited to, kits and packages.
  • the article of manufacture of the present invention comprises: (a) a first container; (b) a pharmaceutical composition located within the first container, wherein the composition, comprises: a first therapeutic agent, comprising a compound of the present invention or a pharmaceutically acceptable salt form thereof; and, (c) a package insert stating that the pharmaceutical composition can be used for the treatment of dyslipidemias and the sequelae thereof.
  • the package insert states that the pharmaceutical composition can be used in combination (as defined previously) with a second therapeutic agent for the treatment of fibrosis and the sequelae thereof.
  • the article of manufacture can further comprise: (d) a second container, wherein components (a) and (b) are located within the second container and component (c) is located within or outside of the second container. Located within the first and second containers means that the respective container holds the item within its boundaries.
  • the first container is a receptacle used to hold a pharmaceutical composition.
  • This container can be for manufacturing, storing, shipping, and/or individual/bulk selling.
  • First container is intended to cover a bottle, jar, vial, flask, syringe, tube (e.g., for a cream preparation), or any other container used to manufacture, hold, store, or distribute a pharmaceutical product.
  • the second container is one used to hold the first container and, optionally, the package insert.
  • the second container include, but are not limited to, boxes (e.g., cardboard or plastic), crates, cartons, bags (e.g., paper or plastic bags), pouches, and sacks.
  • the package insert can be physically attached to the outside of the first container via tape, glue, staple, or another method of attachment, or it can rest inside the second container without any physical means of attachment to the first container.
  • the package insert is located on the outside of the second container. When located on the outside of the second container, it is preferable that the package insert is physically attached via tape, glue, staple, or another method of attachment. Alternatively, it can be adjacent to or touching the outside of the second container without being physically attached.
  • the package insert is a label, tag, marker, etc. that recites information relating to the pharmaceutical composition located within the first container.
  • the information recited will usually be determined by the regulatory agency governing the area in which the article of manufacture is to be sold (e.g. , the United States Food and Drug Administration).
  • the package insert specifically recites the indications for which the
  • the package insert may be made of any material on which a person can read information contained therein or thereon.
  • the package insert is a printable material (e.g. , paper, plastic, cardboard, foil, adhesive- backed paper or plastic, etc.) on which the desired information has been formed (e.g., printed or applied).
  • Optically active forms may be prepared by resolution of racemic forms or by synthesis from optically active starting materials. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention. When enantiomeric or diastereomeric products are prepared, they may be separated by conventional methods, for example, by chromatography or fractional crystallization.
  • the end products of the present invention are obtained either in free (neutral) or salt form. Both the free form and the salts of these end products are within the scope of the invention. If so desired, one form of a compound may be converted into another form. A free base or acid may be converted into a salt; a salt may be converted into the free compound or another salt; a mixture of isomeric compounds of the present invention may be separated into the individual isomers. Compounds of the present invention, free form and salts thereof, may exist in multiple tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged.
  • a compound of the invention or “compounds of the invention” means one or more compounds encompassed by any one of Formula (I), (Ila), and (lib), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof.
  • alkyl or “alkylene” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. While “alkyl” denotes a monovalent saturated aliphatic radical (such as ethyl), “alkylene” denotes a bivalent saturated aliphatic radical (such as ethylene). For example, “Ci to Cio alkyl” or “Ci-io alkyl” is intended to include Ci, C 2 , C3, C 4 , C5, Ce, C7, Ce, Cs>, and Cio alkyl groups.
  • Ci to Cio alkylene or “Ci-10 alkylene” is intended to include Ci, C 2 , C3, C 4 , C5, Ce, C7, Ce, Cs>, and Cio alkylene groups. Additionally, for example, “Ci to Ce alkyl” or “Ci-6 alkyl” denotes alkyl having 1 to 6 carbon atoms; and “Ci to Ce alkylene” or “Ci-6 alkylene” denotes alkylene having 1 to 6 carbon atoms.
  • Alkyl group can be unsubstituted or substituted with at least one hydrogen being replaced by another chemical group.
  • Example alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g.
  • n-propyl and isopropyl e.g. , n-propyl and isopropyl
  • butyl e.g. , n-butyl, isobutyl, i-butyl
  • pentyl e.g. , n-pentyl, isopentyl, neopentyl
  • lower alkyl as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons containing 1 to 8 carbons
  • alkyl and alk as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4- dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like.
  • Heteroalkyl refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S.
  • a heteroatom e.g. , O, N, or S
  • the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g. , -OCH3, etc.), an alky lamino (e.g. , -NHCH3, -N(CH3)2, etc.), or a thioalkyl group (e.g. , -SCH3).
  • a nonterminal carbon atom of the alkyl group which is not attached to the parent molecule is replaced with a heteroatom (e.g. , O, N, or S) and the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g. , -CH2CH2-O-CH3, etc.), an alkylaminoalkyl
  • a terminal carbon atom of the alkyl group is replaced with a heteroatom (e.g. , O, N, or S), the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g. , -CH2CH2-OH), an aminoalkyl group (e.g., -CH2NH2), or an alkyl thiol group (e.g. , -CH2CH2-SH).
  • a heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • a Ci- Ce heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
  • alkenyl or “alkenylene” is intended to include hydrocarbon chains of either straight or branched configuration having the specified number of carbon atoms and one or more, preferably one to two, carbon-carbon double bonds that may occur in any stable point along the chain. While “alkenyl” denotes a monovalent radical, “alkenylene” denotes a bivalent radical. For example, “C2 to Ce alkenyl” or “C2-6 alkenyl” (or alkenylene), is intended to include C2, C3, C 4 , C5, and Ce alkenyl groups.
  • alkenyl examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3, pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, and 4-methyl-3-pentenyl.
  • Alkynyl or alkynylene is intended to include hydrocarbon chains of either straight or branched configuration having one or more, preferably one to three,
  • alkynyl denotes a monovalent radical
  • alkynylene denotes a bivalent radical
  • C2 to Ce alkynyl or “C2-6 alkynyl” (or alkynylene) is intended to include C2, C3, C 4 , C5, and Ce alkynyl groups; such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
  • arylalkyl (a.k.a. aralkyl), “heteroarylalkyl” “carbocyclylalkyl” or “heterocyclylalkyl” refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an aryl, heteroaryl, carbocyclyl, or heterocyclyl radical, respectively.
  • Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l -yl, naphthylmethyl, 2- naphthylethan-l-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like.
  • the arylalkyl, heteroarylalkyl, carbocyclylalkyl, or heterocyclylalkyl group can comprise 4 to 20 carbon atoms and 0 to 5 heteroatoms, e.g., the alkyl moiety may contain 1 to 6 carbon atoms.
  • lower alkoxy refers to any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.
  • "Ci to Ce alkoxy” or “Ci-6 alkoxy” (or alkyloxy) is intended to include Ci, C 2 , C3, C 4 , C5, and Ce alkoxy groups.
  • Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), and i-butoxy.
  • lower alkylthio represents an alkyl, aryl, or aralkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example methyl-S- and ethyl-S-.
  • alkanoyl or “alkylcarbonyl” as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.
  • alkylcarbonyl may be represented by alkyl-C(O)-.
  • Ce to Ce alkylcarbonyl (or alkylcarbonyl), is intended to include Ci, C2, C3, C 4 , C5, and Ce alkyl-C(O)- groups.
  • alkylsulfonyl or “sulfonamide” as used herein alone or as part of another group refers to alkyl or amino linked to a sulfonyl group.
  • alkylsulfonyl may be represented by -S(0)2R', while sulfonamide may be represented by -S(0)2NR c R d .
  • R' is Ci to Ce alkyl; and R c and R d are the same as defined below for "amino".
  • carbamate as used herein alone or as part of another group refers to oxygen linked to an amido group.
  • carbamate may be represented by
  • N(R c R d )-C(0)-O, and R c and R d are the same as defined below for "amino".
  • amido as used herein alone or as part of another group refers to amino linked to a carbonyl group.
  • amido may be represented by N(R c R d )-C(0)-, and R c and R d are the same as defined below for "amino".
  • amino is defined as -NR cl R c2 , wherein R cl and R c2 are independently H or Ci-6 alkyl; or alternatively, R cl and R c2 , taken together with the atoms to which they are attached, form a 3- to 8-membered heterocyclic ring which is optionally substituted with one or more group selected from halo, cyano, hydroxyl, amino, oxo, Ci-6 alkyl, alkoxy, and aminoalkyl.
  • R cl or R c2 (or both of them) is Ci-6 alkyl
  • the amino group can also be referred to as alkylamino.
  • alkylamino group include, without limitation, -NH2, methylamino, ethylamino, propylamino, isopropylamino and the like.
  • aminoalkyl refers to an alkyl group on which one of the hydrogen atoms is replaced by an amino group.
  • aminoalkyl may be represented by N(R cl R c2 )- alkylene-.
  • Ci to Ce or “Ci- ⁇ ” aminoalkyl” (or aminoalkyl), is intended to include Ci, C2, C3, C 4 , C5, and Ce aminoalkyl groups.
  • halogen or "halo” as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine, with chlorine or fluorine being preferred.
  • Haloalkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with one or more halogens.
  • Ce to Ce haloalkyl or “Ci-6 haloalkyl” (or haloalkyl) (or haloalkyl) is intended to include Ci, C 2 , C3, C 4 , C5, and Ce haloalkyl groups. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl,
  • haloalkyl also include "fluoroalkyl” that is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more fluorine atoms.
  • fluoroalkyl refers to an "alkyl” group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or CI, preferably F, such as polyfluoroalkyl, for example, CF3CH2, CF3 or CF3CF2CH2.
  • Haloalkoxy or "haloalkyloxy” represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • “Ci to Ce haloalkoxy” or “Ci-6 haloalkoxy” is intended to include Ci, C2, C3, C 4 , C5, and Ce haloalkoxy groups.
  • Examples of haloalkoxy include, but are not limited to,
  • haloalkoxy also include "fluoroalkoxy" which represents a fluoroalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • haloalkylthio or “thiohaloalkoxy” represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example trifluoromethyl-S-, and pentafluoroethyl-S-.
  • polyhaloalkyloxy refers to an "alkoxy” or “alkyloxy” group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or CI, preferably F, such as
  • polyfluoroalkoxy for example, -OCH2CF3, -OCF3, or -OCH2CF2CF3.
  • “Hydroxyalkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more hydroxyl (OH).
  • “Ci to Ce hydroxyalkyl” (or hydroxyalkyl), is intended to include Ci, C2, C3, C 4 , C5, and Ce hydroxyalkyl groups.
  • cycloalkyl refers to cyclized alkyl groups, including mono-, bi- or poly-cyclic ring systems. "C3 to C7 cycloalkyl” or “C3-7 cycloalkyl” is intended to include
  • Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornyl. Branched cycloalkyl groups such as 1 -methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl".
  • cycloheteroalkyl refers to cyclized heteroalkyl groups, including mono-, bi- or poly-cyclic ring systems.
  • C3 to C7 cycloheteroalkyl or “C3-7 cycloheteroalkyl” is intended to include C3, C 4 , C5, Ce, and C7 cycloheteroalkyl groups.
  • cycloheteroalkyl groups include, but are not limited to, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl.
  • Branched cycloheteroalkyl groups such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyridizylmethyl, pyrimidylmethyl, and
  • pyrazinylmethyl are included in the definition of "cycloheteroalkyl” .
  • azacyclyl refers to a cycloheteroalkyl containing one or more nitrogen atoms in the ring.
  • Example azacyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl.
  • carrier As used herein, “carbocycle”, “carbocyclyl”, or “carbocyclic” is intended to mean any stable 3-, 4-, 5-, 6-, 7-, or 8-membered monocyclic or 5-, 6-, 7-, 8-, 9-, 10-, 1 1-, 12-, or 13-membered poly cyclic (including bicyclic or tricyclic) hydrocarbon ring, any of which may be saturated or partially unsaturated. That is, the term “carbocycle”, “carbocyclyl”, or “carbocyclic” includes, without limitation, cycloalkyl and cycloalkenyl.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane,
  • bridged rings are also included in the definition of carbocycle (e.g. , [2.2.2]bicyclooctane).
  • Preferred carbocycles are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, indanyl, and tetrahydronaphthyl.
  • a bridged ring occurs when one or more, preferably one to three, carbon atoms link two non-adjacent carbon atoms.
  • Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.
  • carbocyclyl including “cycloalkyl” and “cycloalkenyl”, as employed herein alone or as part of another group includes saturated or partially unsaturated
  • cyclic hydrocarbon groups containing 1 to 3 rings including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 10 carbons or 3 to 6 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,
  • any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, nitro, cyano, thiol and/or alkylthio and/or any of the alkyl substituents.
  • substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, nitro, cyano, thiol and/or alkylthio and/or any of the alkyl substituents.
  • bicyclic carbocycle or "bicyclic carbocyclic group” is intended to mean a stable 9- or 10-membered carbocyclic ring system that contains two fused rings and consists of carbon atoms. Of the two fused rings, one ring is a benzo ring fused to a second ring; and the second ring is a 5- or 6-membered carbon ring which is saturated or partially unsaturated.
  • the bicyclic carbocyclic group may be attached to its pendant group at any carbon atom which results in a stable structure.
  • the bicyclic carbocyclic group described herein may be substituted on any carbon if the resulting compound is stable. Examples of a bicyclic carbocyclic group are, but not limited to, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and indanyl.
  • aryl refers to monocyclic or poly cyclic (including bicyclic and tricyclic) aromatic hydrocarbons, including, for example, phenyl, naphthyl, anthracenyl, and phenanthranyl.
  • Aryl moieties are well known and described, for example, in Lewis, R.J., ed., Hawley's Condensed Chemical Dictionary, 13th Edition, John Wiley & Sons, Inc., New York (1997).
  • aryl denotes monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1 - naphthyl and 2-naphthyl).
  • aryl denotes monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1 - naphthyl and 2-naphthyl).
  • Cio aryl or C6-10 aryl refers to phenyl and naphthyl.
  • aryl may be unsubstituted or substituted with 1 to 5 groups, preferably 1 to 3 groups, selected from -OH, -OCH 3 , F, CI, Br, I, -CN, -NO2, -NH2, -N(CH 3 )H, -N(CH 3 ) 2 , -CF 3 , -OCF 3 , -C(0)CH 3 , -SCH 3 , -S(0)CH 3 , -S(0) 2 CH 3 , -CH 3 , -CH 2 CH 3 , -CO2H, and -C0 2 CH 3 .
  • heterocycle As used herein, the term “heterocycle”, “heterocyclyl”, or “heterocyclic group” is intended to mean a stable 3-, 4-, 5-, 6-, or 7-membered monocyclic or 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered poly cyclic (including bicyclic and tricyclic) heterocyclic ring that is saturated, or partially unsaturated, and that contains carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S; and including any poly cyclic group in which any of the above-defined heterocyclic rings is fused to a carbocyclic or an aryl (e.g., benzene) ring.
  • aryl e.g., benzene
  • heterocycle includes non-aromatic ring systems, such as heterocycloalkyl and heterocycloalkenyl.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized (i.e. , N ⁇ 0 and S(0) P , wherein p is 0, 1 or 2).
  • the nitrogen atom may be substituted or unsubstituted (i. e. , N or NR wherein R is H or another substituent, if defined).
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.
  • Examples of hetercyclyl include, without limitation, azetidinyl, piperazinyl, piperidinyl, piperidonyl, piperonyl, pyranyl, morpholinyl, tetrahydrofuranyl,
  • bicyclic heterocycle or "bicyclic heterocyclic group” is intended to mean a stable 9- or 10-membered heterocyclic ring system which contains two fused rings and consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O and S. Of the two fused rings, one ring is a 5- or 6-membered monocyclic aromatic ring comprising a 5-membered heteroaryl ring, a
  • the second ring is a 5- or 6-membered monocyclic ring which is saturated, partially unsaturated, or unsaturated, and comprises a 5-membered heterocycle, a 6-membered heterocycle or a carbocycle (provided the first ring is not benzo when the second ring is a carbocycle).
  • the bicyclic heterocyclic group may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • the bicyclic heterocyclic group described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. Examples of a bicyclic heterocyclic group are, but not limited to,
  • Bridged rings are also included in the definition of heterocycle.
  • a bridged ring occurs when one or more, preferably one to three, atoms (i.e. , C, O, N, or S) link two non-adjacent carbon or nitrogen atoms.
  • Examples of bridged rings include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.
  • heteroaryl is intended to mean stable monocyclic and poly cyclic (including bicyclic and tricyclic) aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.
  • Heteroaryl groups include, without limitation, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl,
  • benzodioxolanyl and benzodioxane.
  • Heteroaryl groups are substituted or unsubstituted.
  • the nitrogen atom is substituted or unsubstituted (i.e. , N or NR wherein R is H or another substituent, if defined).
  • the nitrogen and sulfur heteroatoms may optionally be oxidized (i.e. , N ⁇ 0 and S(0) P , wherein p is 0, 1 or 2).
  • heteroaryl examples include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl,
  • benzisothiazolyl benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-l,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, imidazolopyridinyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolopyridinyl, isoxazolyl, iso
  • 5- to 10-membered heteroaryl examples include, but are not limited to, pyridinyl, furanyl, thienyl, pyrazolyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxazolidinyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, lH-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl,
  • benzotriazolyl benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl.
  • Examples of 5- to 6-membered heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxazolidinyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl.
  • Carbocyclyl or “heterocyclyl” includes one to three additional rings fused to the carbocyclic ring or the heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings, for example,
  • cycloheteroalkylalkyl aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, alkoxycarbonyl, arylcarbonyl, arylalkenyl, aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, aminocarbonyl, alkylcarbony
  • alkyl alkenyl, alkynyl, cycloalkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl
  • the number of carbon atoms and ring members are the same as those defined in the terms by themselves.
  • alkoxy, haloalkoxy, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, haloalkoxy, alkoxyalkoxy, haloalkylamino, alkoxyalkylamino, haloalkoxyalkylamino, alkylthio, and the like each independently contains the number of carbon atoms which are the same as defined for the term "alkyl", such as 1 to 4 carbon atoms, 1 to 6 carbon atoms, 1 to 10 carbon atoms, etc.
  • each indepdent contains ring members which are the same as defined for the terms "cycloalkyl", “heterocyclyl”, “aryl”, and “heteroaryl”, such as 3 to 6-membered, 4 to 7- membered, 6 to 10-membered, 5 to 10-membered, 5 or 6-membered, etc.
  • X' Y' is used to depict a stereogenic center of the carbon atom to which X', Y', and Z' are attached and is intended to represent both enantiomers in a single figure. That is, a structural formula with such as wavy bond denotes each of the enantiomers individually, such as x ' X Y' or X' A Y' , as well as a racemic mixture thereof.
  • substituents and other moieties of the compounds of the present invention should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition.
  • Compounds of the present invention which have such stability are contemplated as falling within the scope of the present invention.
  • counter ion is used to represent a negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.
  • metal ion refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.
  • substituted means that at least one hydrogen atom (attached to carbon atom or heteroatom) is replaced with a non-hydrogen group, provided that normal valencies are maintained and that the substitution results in a stable compound.
  • 2 hydrogens on the atom are replaced.
  • Oxo substituents are not present on aromatic moieties.
  • a ring system e.g. , carbocyclic or heterocyclic
  • the carbonyl group or double bond be part (i.e. , within) of the ring.
  • substituted in reference to alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, alkylene, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, and heterocyclyl, means alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, alkylene, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, and heterocyclyl, respectively, in which one or more hydrogen atoms, which are attached to either carbon or heteroatom, are each independently replaced with one or more non-hydrogen substituent(s).
  • nitrogen atoms e.g., amines
  • these may be converted to N-oxides by treatment with an oxidizing agent (e.g., mCPBA and/or hydrogen peroxides) to afford other compounds of this invention.
  • an oxidizing agent e.g., mCPBA and/or hydrogen peroxides
  • shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N-oxide (N ⁇ 0) derivative.
  • any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence.
  • a group is shown to be substituted with 0, 1, 2, or 3 R groups, then said group be unsubstituted when it is substituted with 0 R group, or be substituted with up to three R groups, and at each occurrence R is selected independently from the definition of R.
  • tautomer refers to each of two or more isomers of a compound that exist together in equilibrium, and are readily interchanged by migration of an atom or group within the molecule
  • 1,2,3-triazole as defined above:
  • this disclosure is intended to cover all possible tautomers even when a structure depicts only one of them.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, and/or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the compounds of the present invention can be present as salts, which are also within the scope of this invention.
  • Pharmaceutically acceptable salts are preferred.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Easton, PA (1990), the disclosure of which is hereby incorporated by reference.
  • the compounds of the present invention can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms, for example acetic acid, which are unsubstituted or substituted, for example, by halogen as chloroacetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxy carboxylic acids, for example ascorbic, gly colic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C1-C4)
  • Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center.
  • the compounds of the present invention having at least one acid group can also form salts with bases.
  • Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono, di or tri-lower alkylamine, for example ethyl, tert-butyl, diethyl, diisopropyl, triethyl, tributyl or dimethyl-propylamine, or a mono, di or trihydroxy lower alkylamine, for example mono, di or triethanolamine.
  • Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds of
  • Preferred salts of the compounds of Formula (I) which contain a basic group include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate, nitrate or acetate.
  • Preferred salts of the compounds of Formula (I) which contain an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amines.
  • the compounds of the present invention may have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent is a prodrug within the scope and spirit of the invention.
  • prodrug encompasses both the prodrugs based on the carboxylic acid residue, i.e., “prodrug esters”, and the prodrugs based on the arginine mimetics moiety, i.e., "prodrugs of arginine mimetics"
  • prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes. Parenteral administration may be used where the ester per se is active, or in those instances where hydrolysis occurs in the blood.
  • the compounds of the present invention contain a carboxy group which can form physiologically hydrolyzable esters that serve as prodrugs, i.e., "prodrug esters", by being hydrolyzed in the body to yield the compounds of the present invention per se.
  • physiologically hydrolyzable esters of compounds of the present invention include Ci to Ce alkyl, Ci to e alkylbenzyl, 4-methoxy benzyl, indanyl, phthalyl, methoxymethyl, Ci-6 alkanoyloxy-Ci-6 alkyl (e.g. , acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl), Ci to e alkoxycarbonyloxy-Ci to e alkyl (e.g. , methoxycarbonyl-oxymethyl or
  • esters 5-methyl-2-oxo-l ,3-dioxolen-4-yl)-methyl
  • esters may be prepared by conventional techniques known in the art.
  • the "prodrug esters” can be formed by reacting the carboxylic acid moiety of the compounds of the present invention with either alkyl or aryl alcohol, halide, or sulfonate employing procedures known to those skilled in the art.
  • various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:
  • prodrugs Preparation of prodrugs is well known in the art and described in, for example, King, F.D., ed., Medicinal Chemistry: Principles and Practice, The Royal Society of Chemistry, Cambridge, UK (1994); Testa, B. et al, Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology, VCHA and Wiley -VCH, Zurich, Switzerland (2003); Wermuth, C.G., ed., The Practice of Medicinal Chemistry, Academic Press, San Diego, CA (1999); Rautio, J. et al, Nature Review Drug Discovery, 17, 559-587, (2016).
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium (symbol D or 2 H) and tritium (symbol T or 3 ⁇ 4).
  • Isotopes of carbon include 1 C and 14 C.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds have a variety of potential uses, e.g. , as standards and reagents in determining the ability of a potential pharmaceutical compound to bind to target proteins or receptors, or for imaging compounds of this invention bound to biological receptors in vivo or in vitro.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. It is preferred that compounds of the present invention do not contain a N-halo, S(0)2H, or S(0)H group.
  • solvate means a physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding.
  • the solvent molecules in the solvate may be present in a regular arrangement and/or a non-ordered arrangement.
  • the solvate may comprise either a stoichiometric or nonstoichiometric amount of the solvent molecules.
  • “Solvate” encompasses both solution-phase and isolable solvates.
  • Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.
  • glycosyl means a monovalent free radical or substituent moiety obtained by removing the hemiacetal hydroxyl group from the cyclic form of a monosaccharide and, by extension, of a lower oligosaccharide.
  • the glycosyl group has the following structure:
  • GMF glass microfiber filter Grubbs II (l,3-bis(2,4,6 rimethylphenyl)-2-imidazolidinylidene)dichloro (phenylmethylene)(triycyclohexylphosphine)ruthenium
  • RuPhos-Pd-G2 chloro(2-dicyclohexylphosphino-2',6'-diisopropoxy-l,l '- biphenyl)[2-(2'-amino-l , 1 '-biphenyl)]palladium(II)
  • the compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby
  • the compounds of the present invention may be prepared using the reactions and techniques described in this section.
  • the reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected.
  • all proposed reaction conditions including solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art.
  • One skilled in the art of organic synthesis understands that the functionality present on various portions of the edict molecule must be compatible with the reagents and reactions proposed. Not all compounds of Formula (I) falling into a given class may be compatible with some of the reaction conditions required in some of the methods described.
  • Compounds of the present invention represented by Formula (I), Formula (II), Formula (III), or any subgenera or species thereof, can be prepared according to the general routes shown in SCHEMES 1 to 13 below.
  • Scheme 1 describes a method of preparing compounds of Formula I-a, I-b, and I-c, a subset of Formula I.
  • Intermediate 1 can be converted to products I-a through coupling with X ⁇ I ⁇ -Z-R* (X 5 is a halogen, triflate or other suitable leaving group, and are commercially available or readily prepared by methods known to one skilled in the art) under conditions that are well-known to one skilled in the art.
  • X 5 is a halogen, triflate or other suitable leaving group, and are commercially available or readily prepared by methods known to one skilled in the art.
  • L 1 represents a covalent bond
  • products I-a can be obtained through a variety of C-N bond forming reactions between intermediate 1 and a suitable aryl halide, triflate or equivalent.
  • Some examples include, but are not limited to, Pd-catalyzed Buchwald-Hartwig reaction, Cu-mediated Ullmann coupling, Ni-mediated animation, or nucleophilic aromatic substitution (SNAT).
  • the Cu-catalyzed Chan-Evans-Lam coupling can be employed with a boronic acid or ester coupling partner.
  • optimization of variables such as catalyst, ligand, solvent, base, additives and temperature may be required.
  • L 1 represents a linker such as, but not limited to, CO or SO2.
  • products I-a can be obtained through the coupling of intermediate 1 with a suitable carboxylic acid utilizing coupling reagents such as but not limited to, T3P, EDC, DCC or CDI in the presence of a suitable base, for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • a suitable base for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • carboxylic acid chlorides or sulfonyl chlorides may be reacted with intermediate 1 in order to obtain I-a by stirring in an appropriate solvent such as dichloromethane in the presence of a base such as triethylamine or Hunig's base.
  • I-a contains an ester or nitrile it can be hydrolyzed to the corresponding carboxylic acid I-b under conditions such as but not limited to treatment of I-a with NaOH or LiOH in solvents consisting of MeOH, THF, and water at a temperature suitable to enable the hydrolysis.
  • Acid-mediated hydrolysis of particular esters, such as a fert-butyl ester, may be required in some cases to obtain I-b.
  • Examples I-c can be obtained by the coupling of I-b with R 1 -NH-R 14 utilizing coupling reagents such as but not limited to, T3P, EDC, DCC or CDI in the presence of a suitable base, for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • a suitable base for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • a suitable base for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • Scheme 2 describes a method for the preparation of intermediates la, lb, and lc, a subset of intermediate 1.
  • the coupling of intermediates 2, where X 6 is CI, Br or I, and ketones 3 can be accomplished through a variety of conditions such as formation of the aryl Grignard, aryl lithium, aryl zinc or other aryl metal species of 2 with subsequent addition to the ketone 3 to give tertiary alcohol products 4.
  • Scheme 3 describes an alternative method for the synthesis of intermediate la.
  • Ketones 3 can be converted to the corresponding boronic acid or ester in two steps consisting of enol triflate formation and subsequent Miyaura borylation.
  • Triflate formation can be accomplished by treating 3 with a base such as LiHMDS at low temperature in THF followed by addition of Comin's reagent or another suitable triflate donor source.
  • Typical conditions for Miyaura borylation include, but are not limited to heating the intermediate triflate with bis(pinacolato)diboron (B2Pin2), potassium acetate and a palladium catalyst such as PdCh(dppf)2 in a suitable solvent such as THF or dioxane.
  • Heteroaryl halide intermediate 2 can undergo Suzuki coupling with boronic acid or boronic ester 5 to yield alkene 6.
  • Typical conditions for the Suzuki coupling include, but are not limited to, heating the intermediates 2 and 5 together with a palladium catalyst, ligand and base at a suitable temperature in a deoxygenated solvent or solvent mixture.
  • Specific conditions include, but are not limited to Pd(OAc)2, DPEPhos, K3PO4 in dioxane/water at 90°C.
  • the specific conditions utilized to obtain 6, including stoichiometry, palladium source, ligand, base, solvent, temperature, and concentration may require independent optimization.
  • Scheme 4 describes a method for preparing intermediate Id, a subset of intermediate 1.
  • Intermediate 7 can undergo condensation with diol 8 (commercially available or readily prepared by methods known to one skilled in the art) under mildly-acidic dehydrating conditions to yield acetal 9.
  • Conditions for the conversion of 7 to 9 include, but are not limited to, refluxing 7 and 8 in a solvent such as toluene in the presence of 4A molecular sieves and catalytic /?-TSA.
  • additional methods for protecting group removal may be found in Greene, T. and Wuts, P. G. M., Protecting Groups in Organic Synthesis, John Wiley & Sons, Inc., New York, NY, 2006 and references therein.
  • Scheme 5 describes a method for preparing intermediate le, a subset of intermediate 1.
  • Intermediate aldehyde 7 can be converted to diol 10 in two steps comprising alkenylation and dihydroxylation.
  • the alkenylation step can be accomplished with a reagent such as methyl triphenylphosphonium bromide and a suitable base such as, but not limited to KO ⁇ Bu or NaHMDS in a solvent such as THF.
  • a suitable base such as, but not limited to KO ⁇ Bu or NaHMDS
  • scheme 6 describes a method for the preparation of compounds I-d and I-e a subset of formula I.
  • Intermediate 14 can be obtained through a variety of coupling reactions between amino ketone 13 (commercially available or readily prepared by methods known to one skilled in the art) and a suitable aryl halide, triflate or equivalent
  • X ⁇ I ⁇ -Z-R* where X 5 represents the halide or triflate.
  • Some examples of such coupling reactions include, but are not limited to, Pd-catalyzed Buchwald-Hartwig reaction, Cu- mediated Ullmann coupling, Ni-mediated amination, or nucleophilic aromatic substitution (SNAT) to give intermediate 14.
  • SNAT nucleophilic aromatic substitution
  • products I-d contain an ester or nitrile they can be hydrolyzed to the corresponding carboxylic acid I-e under conditions such as but not limited to treatment of I-d with NaOH or LiOH in solvents consisting of MeOH, THF, and water at a temperature suitable to enable the hydrolysis.
  • Acid-mediated hydrolysis of particular esters, such as a fert-butyl ester, may be required in some cases to obtain I-e.
  • Scheme 7 describes a method for preparing intermediate 2a, a subset of intermediate 2.
  • Aldehydes 15 (commercially available or readily prepared by methods known to one skilled in the art) can be condensed with hydroxylamine hydrochloride under a variety of conditions including, but not limited to, stirring both reactants in pyridine at room temperature, or gently heating the reactants in the presence of a base like sodium hydroxide or sodium acetate in a suitable solvent such as ethanol.
  • the resultant oximes can be converted to the corresponding hydroximoyl halides 16 through halogenation by reagents such as but not limited to NCS or NBS in a suitable solvent such as DMF.
  • the hydroximoyl halides 16 undergo annulation with terminal alkynes (commercially available or readily prepared by one skilled in the art) under conditions such as, but not limited to triethyl amine in dichloromethane at room temperature to afford 3,5-substituted isoxazoles 17.
  • the 4- position of the isoxazole can be halogenated by reagents such as but not limited to NBS or NCS in a suitable solvent such as DMF to give 3,4,5-substituted isoxazole intermediates 2a.
  • Scheme 8 describes a method of preparing intermediate 2b, a subset of intermediate 2.
  • the synthesis can commence with azidation of amine 18a (commercially available or readily prepared by methods known to one skilled in the art) under conditions such as, but not limited to, treatment with sodium nitrite in acidic media (H2O/TFA) followed by addition of sodium azide in an appropriate solvent at a suitable temperature to give azide 19.
  • azide 19 can be obtained by the reaction of halide 18b (commercially available or readily prepared by methods known to one skilled in the art) with an azide salt, such as sodium azide, in a mixture of DMSO/water at an appropriate temperature.
  • the resultant azide 19 can be annulated with a commercially available terminal alkyne to give iodotriazole intermediate 2b under conditions such as, but not limited to, copper (II) perchlorate, potassium iodide, and DBU in THF at room temperature.
  • iodotriazole intermediate 2b under conditions such as, but not limited to, copper (II) perchlorate, potassium iodide, and DBU in THF at room temperature.
  • Scheme 9 describes a method of preparing intermediate 2c, a subset of intermediate 2.
  • Commercially available or readily prepared N-substituted glycines 20 give sydnones 21 when treated with sodium nitrite, HC1 and acetic anhydride under conditions that can be found in Fang, Y.; Wu, C; Larock, R. C; Shi, F. J. Org. Chem. 2011, 76, 8840.
  • the sydnones 21 can be converted to pyrazole intermediates 2c in a two-step process involving bromination with NBS followed by copper catalyzed cycloaddition with an alkyne as described in Decuypere, E.; Specklin, S.; Gabillet, S.; Audisio, D.; Liu, H.; Plougastel, L.; Kolodych S.; Taran, F. Org. Lett. 2015, 77, 362.
  • Scheme 10 describes a method for preparing intermediate 4a, a subset of intermediate 4.
  • An appropriately substituted boronic acid or ester 22 (commercially available or readily prepared by methods known to one skilled in the art) and a pyrazole 23 bearing a suitably reactive halogen or equivalent X, (commercially available or readily prepared by methods known to one skilled in the art) can be coupled through the Pd- catalyzed Suzuki reaction to give intermediate 24.
  • Typical conditions for the Suzuki coupling include, but are not limited to, heating the reactants 22 and 23 together with a palladium catalyst, ligand and base at a suitable temperature in a deoxygenated solvent or solvent mixture.
  • Specific conditions include, but are not limited to PdCl2(dppf)2, Na2C03 in THF/water at 120°C.
  • specific conditions utilized to obtain 24 including stoichiometry, palladium source, ligand, base, solvent, temperature, and concentration may require independent optimization.
  • the coupling partners 22 and 23, are either commercially available or can be readily prepared by methods known to one skilled in the art.
  • Intermediate 24 can be deprotonated at the 5-position of the pyrazole by a sufficiently strong base such as, but not limited to, w-BuLi, or LDA in a suitable solvent such as THF or Et20.
  • a sufficiently strong base such as, but not limited to, w-BuLi, or LDA
  • a suitable solvent such as THF or Et20.
  • the resulting anion from deprotonation of 24 can be trapped in situ with a ketone 3 to give intermediate 2a.
  • Scheme 11 describes a method of preparing intermediate 7a, a subset of intermediate 7.
  • Hydroximoyl halides 16 (preparation described in Scheme 6) can be reacted with ⁇ - ketoesters (commercially available or readily prepared by methods known to one skilled in the art) in the presence of triethyl amine or another suitable base in a solvent such as, but not limited to, DCM to give 3,4,5-substituted isoxazole esters 25.
  • Reduction of the ester can be accomplished by a number of reagents including, but not limited to L1AIH4, DIBAL-H, or L1BH4 in an appropriate solvent.
  • the resultant hydroxyl of isoxazole 26 can be converted to aldehyde intermediates 7a under oxidative conditions including, but not limited to PCC oxidation, Dess-Martin oxidation, Swem oxidation, Ley oxidation in an appropriate solvent such as, but not limited to DCM or DCE.
  • Scheme 12 describes a method of preparing compounds I-f, I-g, I-h a subset of Formula I.
  • L 1 represents a linker atom such as, but not limited to, O, or N and products I-f can be obtained through the coupling of intermediate 27 with X 5 -Z-R x (X 5 represents a halide or triflate) under conditions that include, but are not limited to, nucleophilic aromatic substitution (SNAr), transition metal mediated arylation (i.e. Pd, Cu, Ni), Mitsunobu coupling, reductive amination or alkylation.
  • I-f contains an ester or nitrile it can be hydrolyzed to the corresponding carboxylic acid I-g under conditions such as but not limited to treatment with NaOH or LiOH in solvents consisting of MeOH, THF, and water at a temperature suitable to enable the hydrolysis.
  • Acid-mediated hydrolysis of particular esters, such as a fert-butyl ester, may be required in some cases to obtain I-g.
  • Examples I-h can be obtained by the coupling of I-g with R 1 -NH-R 14 utilizing coupling reagents such as but not limited to, T3P, EDC, DCC or CDI in the presence of a suitable base, for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • a suitable base for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • a suitable base for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • Scheme 13 describes a method of preparing compounds I-i, I-j, I-k a subset of Formula I.
  • Products I-i can be obtained through coupling of intermediate 28 with X 5 -Z-R x (X 5 represents a halide or triflate) under conditions that include, formation of the aryl Grignard, aryl lithium, aryl zinc or other aryl metal species of X 5 -Z-R x with subsequent addition to 28.
  • I-i contains an ester or nitrile it can be hydrolyzed to the corresponding carboxylic acid I-j under conditions such as but not limited to treatment with NaOH or Li OH in solvents consisting of MeOH, THF, and water at a temperature suitable to enable the hydrolysis.
  • I-j Acid-mediated hydrolysis of particular esters, such as a fert-butyl ester, may be required in some cases to obtain I-j .
  • Examples I-k can be obtained by the coupling of I-j with R 1 -NH-R 15 utilizing coupling reagents such as but not limited to, T3P, EDC, DCC or CDI in the presence of a suitable base, for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • a suitable base for example triethylamine, Hunig's base, or pyridine with or without additives such as HOBT or DMAP in an appropriate solvent such as dichloromethane, ethyl acetate, DMF or THF.
  • a suitable base for example triethylamine, Hunig's base, or pyridine with or without
  • Scheme 14 describes a method for the preparation of intermediates 27a, 27b, and 27c, a subset of intermediate 27.
  • the coupling of heteroaryl halide intermediate 2 and ketone 29 can be accomplished through a variety of conditions such as formation of the aryl Grignard, aryl lithium, aryl zinc or other aryl metal species of 2 with subsequent addition to the ketone 29 to give tertiary alcohol products 30.
  • appropriately acidic conditions i.e. HCl, TFA
  • P* Boc
  • alkenes 27a can be obtained as the primary isolate (deprotection A).
  • HPLC refers to a Shimadzu high performance liquid chromatography instrument with one of following methods:
  • N-Bromosuccinimide (0.81 g, 4.6 mmol) was added to a room temperature solution of 5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole (0.93 g, 3.7 mmol) in DMF (14.6 mL). The reaction mixture was heated to 50 °C. After heating overnight, additional N- bromosuccinimide (0.81 g, 4.6 mmol) was added and heating was continued. After heating for an additional 24 hours the reaction was cooled to room temperature and poured into approximately 100 mL of ice water.
  • n-Butyllithium (8.1 mL, 20.3 mmol) was added slowly to a -78 °C solution of 4- bromo-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole (5.4 g, 16.2 mmol) in THF (64.9 mL) giving a light brown solution.
  • fert-butyl 2-oxo-7- azaspiro[3.5]nonane-7-carboxylate (3.9 g, 16.2 mmol) was added as a solution in 3 mL of THF. The temperature was maintained at -78 °C for 3 hours.
  • Trifluoroacetic acid (8.6 mL, 111.0 mmol) was added to a flask containing fert-butyl 2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-2-hydroxy-7-azaspiro[3.5]nonane-7- carboxylate (5.5 g, 11.2 mmol). The mixture was stirred at room temperature for one hour and the excess TFA was removed in vacuo. The residue was diluted with EtOAc and washed with saturated aqueous K2CO3 and then brine.
  • Example 2 The title compound was prepared as described in General Method A for the preparation of Example 1 with replacement of /er/-butyl 2-oxo-7-azaspiro[3.5]nonane-7- carboxylate with /er/-butyl 3-oxo-l-oxa-8-azaspiro[4.5]decane-8-carboxylate.
  • Zinc-copper couple (28.3 g, 219 mmol) was added to a solution of fert-butyl 3- methylene-8-azabicyclo[3.2.1]octane-8-carboxylate (4.9 g, 21.9 mmol) in diethyl ether (43.0 mL).
  • Trichloroacetyl chloride (13.6 mL, 121 mmol) in DME (21.5 mL) was added and the reaction mixture was stirred at room temperature for 36 h. The reaction was carefully quenched with 1M aqueous K2HPO4 (vigorous bubbling) and then filtered through Celite (Et ⁇ O wash).
  • Example 2 The title compound was prepared as described for the preparation of Example 1 with replacement of fert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate with fert-butyl 3'-oxo- 8-azaspiro[bicyclo[3.2.1]octane-3,l'-cyclobutane]-8-carboxylate.
  • Triethylsilane (70.0 ⁇ , 0.44 mmol) was added to a solution of 2-(2-(5-cyclopropyl-
  • Example 10 The title compound was obtained during the preparation of Example 10 from Pd- mediated dehalogenation during the Buchwald animation step.
  • the title compound could be prepared as described for Example 10 with the replacement of 2,6- dichlorobenzaldehyde with 2-chlorobenzaldehyde.
  • Example 11 The title compound was prepared as described for the preparation of Example 13 with replacement of 2-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-7- azaspiro[3.5]non-l-en-7-yl)-4-fluorobenzo[d]thiazole-6-carboxylic acid (Example 1) with 2-(3'-(5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-8-azaspiro[bicyclo[3.2.1]octane- 3, -cyclobutan]-2'-en-8-yl)-4-fluorobenzo[d]thiazole-6-carboxylic acid (Example 11).
  • Example 12 The title compound was prepared as described for the preparation of Example 15 with replacement of 2-(3'-(5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-8- azaspiro[bicyclo[3.2.1]octane-3, -cyclobutan]-2'-en-8-yl)-4-fluorobenzo[d]thiazole-6- carboxylic acid (Example 11) with 6-(3'-(5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)-8-azaspiro[bicyclo[3.2.1]octane-3, -cyclobutan]-2'-en-8-yl)nicotinic acid (Example 12).
  • Example 17 The title compound was prepared as described in General Method A for the preparation of Example 17 with replacement of ethyl 2-bromo-4-fluorobenzo[d]thiazole-6- carboxylate with methyl 6-chloropyridazine-3-carboxylate.
  • fert-Butyl nitrite (0.28 g, 2.7 mmol) was added slowly to a 0 °C suspension of copper (II) bromide (0.55 g, 2.5 mmol) in acetonitrile (1 1.3 mL). After 5 minutes methyl 2- aminobenzo[d]oxazole-5 -carboxylate (0.43 g, 2.3 mmol) was added and the reaction mixture was brought to room temperature. After stirring overnight, the mixture was concentrated onto S1O2 for purification.
  • Step A T3P (45.2 ⁇ , 0.08 mmol) and Et 3 N (21.4 ⁇ , 0.15 mmol) were added to a solution of 6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)-7- azaspiro[3.5]non-l-en-7-yl)nicotinic acid (Example 30) (19 mg, 0.04 mmol) and methyl 2- aminoacetate, HC1 (9.6 mg, 0.08 mmol) in DCE (0.19 mL).
  • Step B Methyl 2-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)- 7-azaspiro[3.5]non-l-en-7-yl)nicotinamido)acetate (10 mg, 0.02 mmol) was dissolved in THF (136 ⁇ ), water (27.2 ⁇ ,), MeOH (13.6 ⁇ ) and then lithium hydroxide monohydrate (3.7 mg, 0.09 mmol) was added to the mixture. The reaction vessel was sealed and heated to 60 °C. After heating for 2 hours the reaction was quenched with IN HC1 and then concentrated under a stream of nitrogen to minimum volume.
  • Example 30 The title compound was prepared as described for the preparation of Example 31 with replacement of 6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)-7- azaspiro[3.5]non-l-en-7-yl)nicotinic acid (Example 30) with 2-(2-(5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-l-en-7-yl)-4-fluorobenzo[d]thiazole-6- carboxylic acid (Example 29).
  • Example 1 The title compound was obtained as a minor isolate during the preparation of Example 1 in General Method A and was purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 ⁇ 200 mm, 5- ⁇ particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 25-65% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation.
  • Example 29 The title compound was prepared as described in General Method A for the preparation of Example 29 with replacement of fert-butyl 2-oxo-7-azaspiro[3.5]nonane-7- carboxylate with tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate.
  • Example 29 The title compound was prepared as described for the preparation of Example 13 with replacement of 2-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-7- azaspiro[3.5]non-l-en-7-yl)-4-fluorobenzo[d]thiazole-6-carboxylic acid (Example 1) with 2-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-l-en-7-yl)-4- fluorobenzo[d]thiazole-6-carboxylic acid (Example 29).
  • Example 30 The title compound was prepared as described for the preparation of Example 36 with replacement of 2-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)-7- azaspiro[3.5]non-l-en-7-yl)-4-fluorobenzo[d]thiazole-6-carboxylic acid (Example 29) with 6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-l-en-7- yl)nicotinic acid (Example 30).
  • Trifluoroacetic acid (0.10 mL, 1.2 mmol) was added to a room temperature solution of ( ⁇ )-tert-buty ⁇ 2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-l,3-dioxa-8- azaspiro[4.5]decane-8-carboxylate (60 mg, 0.12 mmol) in DCM (2 mL). The reaction mixture was stirred at room temperature overnight. The excess trifluoroacetic acid was removed in vacuo and the residue was partitioned between EtOAc (5 mL) and 1M aqueous K2HPO4 (5 mL).
  • Aqueous LiOH 1.0 M (130 ⁇ , 0.13 mmol) was added to a room temperature solution of ethyl 2-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-l,3-dioxa-8- azaspiro[4.5]decan-8-yl)-4-fluorobenzo[d]thiazole-6-carboxylate (16 mg, 0.03 mmol, Example 38) in 1 : 1 MeOH: THF (260 uL). The reaction mixture was stirred at room temperature overnight and then the excess solvents were removed. Acetic acid was added until ⁇ pH 5 was achieved and the mixture was extracted with dichloromethane (10 mL).
  • Example 39 The title compound was prepared as described General Method C for the preparation of Example 39 with replacement of fert-butyl 4-hydroxy-4-(hydroxymethyl) piperidine-1- carboxylate with tert-butyl (l ⁇ S ⁇ -S-hydroxy-S ⁇ hydroxymethyl) ⁇ - azabicyclo[3.2.1]octane-8-carboxylate.
  • Example 47 The title compound was prepared as described in General Method A for the preparation of Example 47 with replacement of ethyl 2-bromo-4-fluorobenzo[d]thiazole-6- carboxylate with methyl 2-bromo-4-(trifluoromethoxy)benzo[d]thiazole-6-carboxylate.
  • the title compound can be prepared by the two-step procedure described in Example 50 for the preparation of methyl 2-bromo-4-(trifluoromethoxy)benzo[d]thiazole-6- carboxylate with the replacement of methyl 4-amino-3-(trifluoromethoxy)benzoate with ethyl 2-amino-4-methoxybenzoate.
  • Example 51 Example 51.
  • Example 47 The title compound was prepared as described in General Method A for the preparation of Example 47 with replacement of ethyl 2-bromo-4-fluorobenzo[d]thiazole-6- carboxylate with ethyl 2-bromo-5-methoxybenzo[d]thiazole-6-carboxylate.
  • Example 7 The title compound was prepared as described in General Method B for the preparation of Example 7 with replacement of methyl 6-chloro-l-methyl-lH-pyrrolo[2,3- b]pyridine-3-carboxylate with ethyl 7-chlorocinnoline-3-carboxylate, HCl.
  • Example 58 6-(2-(5-Cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)-7- azaspiro[3.5]non-l-en-7-yl)-4-(difluoromethoxy)quinoline-2-carboxylic acid
  • Example 47 The title compound was prepared as described in General Method A for the preparation of Example 47 with replacement of ethyl 2-bromo-4-fluorobenzo[d]thiazole-6- carboxylate with methyl 2-bromo-4-methoxybenzo[d]thiazole-6-carboxylate.
  • Phosphorus oxychloride (0.039 mL, 0.42 mmol) followed by DMF (0.014 mL, 0.18 mmol) were added to a 0 °C solution of 5-(ethoxycarbonyl)-7-(trifluoromethyl) quinoline 1- oxide (0.1 g, 0.35 mmol) in dichloromethane (3.5 mL). After 5 minutes the reaction mixture was brought to room temperature.
  • Example 47 The title compound was prepared as described in General Method A for the preparation of Example 47 with replacement of ethyl 2-bromo-4-fluorobenzo[d]thiazole-6- carboxylate with ethyl 2-chloro-7-(trifluoromethyl)quinoline-5-carboxylate.
  • Example 47 The title compound was prepared as described in General Method A for the preparation of Example 47 with replacement of ethyl 2-bromo-4-fluorobenzo[d]thiazole-6- carboxylate with methyl 2-bromo-4-methylbenzo[d]thiazole-6-carboxylate.
  • Step 1 4-(7-(5-Chlorothiazolo[5,4-b]pyridin-2-yl)-7-azaspiro[3.5]non-l -en-2-yl)-5- cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazole
  • Example 47 The title compound was prepared as described in General Method A for the preparation of Example 47 with replacement of ethyl 2-bromo-4-fluorobenzo[d]thiazole-6- carboxylate with methyl 2-chloro-8-methoxyquinoline-5-carboxylate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (I) ou des stéréoisomères, des tautomères ou des sels pharmaceutiquement acceptables ou des solvates de ceux-ci ; dans la formule, toutes les variables étant telles que définies dans la description. Ces composés modulent l'activité du récepteur farnésoïde X (FXR), par exemple, en tant qu'agonistes. La présente invention concerne également des compositions pharmaceutiques comprenant ces composés et des méthodes de traitement d'une maladie, d'un trouble ou d'un état associé à un dérèglement de FXR, tels que la fibrose pathologique, le rejet de greffe, le cancer, l'ostéoporose et des troubles inflammatoires, à l'aide de composés et de compositions pharmaceutiques selon l'invention.
PCT/US2018/058326 2017-11-01 2018-10-31 Composés spirocycliques à utiliser en tant que modulateurs du récepteur farnésoïde x WO2019089672A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MX2020004400A MX2020004400A (es) 2017-11-01 2018-10-31 Compuestos espirociclicos como moduladores del receptor farnesoide x.
JP2020544335A JP7228595B2 (ja) 2017-11-01 2018-10-31 ファルネソイドｘ受容体モジュレーターとしてのスピロ環化合物
BR112020008157-4A BR112020008157A2 (pt) 2017-11-01 2018-10-31 compostos espirocíclicos como moduladores do receptor farnesoide x
SG11202003825TA SG11202003825TA (en) 2017-11-01 2018-10-31 Spirocyclic compounds as farnesoid x receptor modulators
CA3081424A CA3081424A1 (fr) 2017-11-01 2018-10-31 Composes spirocycliques a utiliser en tant que modulateurs du recepteur farnesoide x
AU2018357878A AU2018357878A1 (en) 2017-11-01 2018-10-31 Spirocyclic compounds as farnesoid X receptor modulators
CN201880069863.0A CN111278821B (zh) 2017-11-01 2018-10-31 作为法尼醇x受体调节剂的螺环化合物
EP18804190.9A EP3704114B1 (fr) 2017-11-01 2018-10-31 Composés spirocycliques en tant que modulateurs du récepteur de farnésoïde x
EA202091101A EA202091101A1 (ru) 2017-11-01 2018-10-31 Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора
ES18804190T ES2933184T3 (es) 2017-11-01 2018-10-31 Compuestos espirocíclicos como moduladores del receptor farnesoide X
KR1020207015273A KR20200083528A (ko) 2017-11-01 2018-10-31 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
PE2020000676A PE20201184A1 (es) 2017-11-01 2018-10-31 Compuestos espirociclicos como moduladores del receptor farnesoide x
IL274322A IL274322A (en) 2017-11-01 2020-04-28 Spirocyclic compounds as paranoid X receptor modulators
CONC2020/0005486A CO2020005486A2 (es) 2017-11-01 2020-04-30 Compuestos espirocíclicos como moduladores del receptor farnesoide x

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580068P 2017-11-01 2017-11-01
US62/580,068 2017-11-01

Publications (1)

Publication Number Publication Date
WO2019089672A1 true WO2019089672A1 (fr) 2019-05-09

Family

ID=64332185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/058326 WO2019089672A1 (fr) 2017-11-01 2018-10-31 Composés spirocycliques à utiliser en tant que modulateurs du récepteur farnésoïde x

Country Status (19)

Country Link
US (1) US11078198B2 (fr)
EP (1) EP3704114B1 (fr)
JP (1) JP7228595B2 (fr)
KR (1) KR20200083528A (fr)
CN (1) CN111278821B (fr)
AR (1) AR113819A1 (fr)
AU (1) AU2018357878A1 (fr)
BR (1) BR112020008157A2 (fr)
CA (1) CA3081424A1 (fr)
CL (1) CL2020001140A1 (fr)
CO (1) CO2020005486A2 (fr)
EA (1) EA202091101A1 (fr)
ES (1) ES2933184T3 (fr)
IL (1) IL274322A (fr)
MX (1) MX2020004400A (fr)
PE (1) PE20201184A1 (fr)
SG (1) SG11202003825TA (fr)
TW (1) TW201922737A (fr)
WO (1) WO2019089672A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021104421A1 (fr) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Forme amorphe de composé tricyclique contenant de l'azote et son utilisation
WO2021144330A1 (fr) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'agonistes de fxr pour traiter une infection par le virus de l'hépatite d
WO2022152770A1 (fr) 2021-01-14 2022-07-21 Enyo Pharma Effet synergique d'un agoniste de fxr et d'ifn pour le traitement d'une infection par le virus de l'hépatite b
WO2022229302A1 (fr) 2021-04-28 2022-11-03 Enyo Pharma Potentialisation forte d'effets d'agonistes de tlr3 à l'aide d'agonistes de fxr en tant que traitement combiné

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592557A (zh) * 2020-05-09 2020-08-28 河北合佳医药科技集团股份有限公司 一种7-氨基-3-乙烯基头孢烷酸的一步法环保制备方法
KR20220153888A (ko) * 2021-05-12 2022-11-21 에이치케이이노엔 주식회사 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087519A1 (fr) * 2010-12-20 2012-06-28 Irm Llc Compositions et procédés pour la modulation de fxr
EP3034501A1 (fr) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy contenant des composés de modulation (FXR NR1H4)
WO2017118294A1 (fr) * 2016-01-06 2017-07-13 广州市恒诺康医药科技有限公司 Modulateur de récepteur fxr, son procédé de préparation et ses utilisations

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
WO1998017276A1 (fr) 1996-10-25 1998-04-30 Merck & Co., Inc. Antagonistes heteroaryle spiroethercycloalkyle de recepteurs de la tachykinine
WO2006006490A1 (fr) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. Composé spirocyclique
CN101248049B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 咪唑类lxr调节剂
WO2007076260A2 (fr) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Agonistes de recepteur de farnesoide x
CN101679297B (zh) * 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
EP2108017A2 (fr) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. Composés d'imidazolone utiles comme antagonistes des récepteurs de tgf-beta type i, alk5 et/ou alk4
MX2009013946A (es) 2007-07-02 2010-03-10 Glaxosmithkline Llc Agonistas del receptor de farnesoide x.
WO2009009059A1 (fr) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Composés spiro en tant qu'antagonistes du tgf-bêta
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
US20110230493A1 (en) 2008-11-21 2011-09-22 Pfizer Inc. 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
JO3154B1 (ar) * 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
AU2013209958B2 (en) * 2012-01-16 2017-09-07 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
JP6258928B2 (ja) 2012-06-13 2018-01-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規ジアザスピロシクロアルカンおよびアザスピロシクロアルカン
US9550793B2 (en) 2012-10-03 2017-01-24 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
US9403810B2 (en) * 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
WO2015172747A1 (fr) 2014-05-16 2015-11-19 Zhaoyin Wang Molécules spirocycliques servant d'inhibiteurs de mth1
EP3034499A1 (fr) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Nouveaux composés de modulation (FXR NR1H4)
CN107106555A (zh) 2014-12-18 2017-08-29 诺华股份有限公司 氮杂双环辛烷衍生物作为fxr激动剂在治疗肝脏和胃肠疾病中的应用
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
WO2017133521A1 (fr) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Agoniste du récepteur fxr
WO2017145040A1 (fr) 2016-02-22 2017-08-31 Novartis Ag Méthodes d'utilisation d'agonistes de fxr
PT3419625T (pt) 2016-02-22 2021-07-07 Novartis Ag Métodos para utilizar agonistas de fxr
WO2017189663A1 (fr) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201155A1 (fr) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
SI3730487T1 (sl) 2016-06-13 2022-08-31 Gilead Sciences, Inc. Azetidinski derivati kot modulatorji FXR (NR1H4)
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087519A1 (fr) * 2010-12-20 2012-06-28 Irm Llc Compositions et procédés pour la modulation de fxr
EP3034501A1 (fr) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy contenant des composés de modulation (FXR NR1H4)
WO2017118294A1 (fr) * 2016-01-06 2017-07-13 广州市恒诺康医药科技有限公司 Modulateur de récepteur fxr, son procédé de préparation et ses utilisations

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
"Design of Prod rugs", 1985, ELSEVIER
"Medicinal Chemistry: Principles and Practice", 1994, THE ROYAL SOCIETY OF CHEMISTRY
"Methods in Enzymology", vol. 112, 1985, ACADEMIC PRESS, pages: 309 - 396
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY
"The Practice of Medicinal Chemistry", 1999, ACADEMIC PRESS
B. M. FORMAN ET AL., CELL, vol. 81, 1995, pages 687
BERG, TRENDS MICROBIOL, vol. 3, 1995, pages 149 - 154
BUNDGAARD, H. ET AL., J. PHARM. SCI., vol. 77, 1988, pages 285
BUNDGAARD, H. ET AL.: "A Textbook of Drug Design and Development", 1991, HARWOOD ACADEMIC PUBLISHERS, article "Design and Application of Prodrugs", pages: 113 - 191
BUNDGAARD, H., ADV. DRUG DELIV. REV., vol. 8, 1992, pages 1 - 38
CRAWLEY, EXPERT OPIN. THER. PATENTS, vol. 20, 2010, pages 1047 - 1057
D. J. PARKS ET AL., SCIENCE, vol. 284, 1999, pages 1365
DECUYPERE, E.; SPECKLIN, S.; GABILLET, S.; AUDISIO, D.; LIU, H.; PLOUGASTEL, L.; KOLODYCH S.; TARAN, F., ORG. LETT., vol. 17, 2015, pages 362
DEGIROLAMO ET AL., HEPATOLOGY, vol. 61, pages 161 - 170
FANG, Y.; WU, C.; LAROCK, R. C.; SHI, F., J. ORG. CHEM., vol. 76, 2011, pages 8840
GREENE, T.; WUTS, P. G. M.: "Protecting Groups in Organic Synthesis", 2006, JOHN WILEY & SONS, INC.
HOLT ET AL., GENES DEV., vol. 17, 2003, pages 1581
IJSSENNAGGER ET AL., J HEPATOL, vol. 64, 2016, pages 1158 - 1166
INAGAKI ET AL., CELL METAB, vol. 2, 2005, pages 217
INAGAKI ET AL., PROC NATL ACAD SCI, vol. 103, 2006, pages 3920 - 3925
KAKEYA, N. ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 692
LAROCK, R.C.: "Comprehensive Organic Transformations", 1989, VCH
LIU ET AL., J. CLIN. INVEST., vol. 112, 2003, pages 1678 - 1687
M. MAKISHIMA ET AL., SCIENCE, vol. 284, 1999, pages 1362
MODICAET, GASTROENTEROLOGY, vol. 142, 2012, pages 355 - 365
MUDALIAR ET AL., GASTROENTEROLOGY, vol. 145, 2013, pages 574 - 582
NEUSCHWANDER-TETRI ET AL., LANCET, vol. 385, 2015, pages 956 - 965
RAUTIO, J. ET AL., NATURE REVIEW DRUG DISCOVERY, vol. 17, 2018, pages 559 - 587
SANYAL ET AL., HEPATOLOGY, vol. 61, 2015, pages 1392 - 1405
TESTA, B. ET AL.: "Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology", 2003, VCHA AND WILEY-VCH
VERNON ET AL., ALIMENT PHARMACOL THER, vol. 34, 2011, pages 274 - 285
W. SEOL ET AL., MOL. ENDOCRINOL., vol. 9, 1995, pages 72
WONG ET AL., HEPATOLOGY, vol. 59, 2014, pages 2188 - 2195
ZHAN ET AL., PLOS ONE, vol. 9, 2014, pages el05930

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021104421A1 (fr) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Forme amorphe de composé tricyclique contenant de l'azote et son utilisation
WO2021144330A1 (fr) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'agonistes de fxr pour traiter une infection par le virus de l'hépatite d
WO2022152770A1 (fr) 2021-01-14 2022-07-21 Enyo Pharma Effet synergique d'un agoniste de fxr et d'ifn pour le traitement d'une infection par le virus de l'hépatite b
WO2022229302A1 (fr) 2021-04-28 2022-11-03 Enyo Pharma Potentialisation forte d'effets d'agonistes de tlr3 à l'aide d'agonistes de fxr en tant que traitement combiné

Also Published As

Publication number Publication date
PE20201184A1 (es) 2020-11-03
TW201922737A (zh) 2019-06-16
IL274322A (en) 2020-06-30
EP3704114A1 (fr) 2020-09-09
ES2933184T3 (es) 2023-02-02
MX2020004400A (es) 2020-08-06
JP2021501806A (ja) 2021-01-21
US11078198B2 (en) 2021-08-03
KR20200083528A (ko) 2020-07-08
AR113819A1 (es) 2020-06-17
CN111278821B (zh) 2023-10-03
BR112020008157A2 (pt) 2020-10-06
CL2020001140A1 (es) 2020-08-21
CA3081424A1 (fr) 2019-05-09
EP3704114B1 (fr) 2022-11-23
SG11202003825TA (en) 2020-05-28
US20190127362A1 (en) 2019-05-02
CN111278821A (zh) 2020-06-12
CO2020005486A2 (es) 2020-05-15
EA202091101A1 (ru) 2020-08-06
JP7228595B2 (ja) 2023-02-24
AU2018357878A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
US11078198B2 (en) Spirocyclic compounds as farnesoid X receptor modulators
KR102506327B1 (ko) αV 인테그린 길항제로서의 인다졸 유도체
US11168079B2 (en) Alkene compounds as farnesoid x receptor modulators
EP3704112B1 (fr) Composés alkène-spirocycliques en tant que modulateurs du récepteur de farnésoïde x
US11370785B2 (en) Multicyclic compounds as farnesoid X receptor modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18804190

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3081424

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020544335

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20207015273

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018804190

Country of ref document: EP

Effective date: 20200602

ENP Entry into the national phase

Ref document number: 2018357878

Country of ref document: AU

Date of ref document: 20181031

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020008157

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020008157

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200424